0001140361-17-046810.txt : 20171219
0001140361-17-046810.hdr.sgml : 20171219
20171219194731
ACCESSION NUMBER: 0001140361-17-046810
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171215
FILED AS OF DATE: 20171219
DATE AS OF CHANGE: 20171219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STAPLETON CRAIG R
CENTRAL INDEX KEY: 0001207106
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37977
FILM NUMBER: 171265439
MAIL ADDRESS:
STREET 1: 55 OLD FIELD POINT ROAD
STREET 2: SUITE 2
CITY: GREENWICH
STATE: CT
ZIP: 06830
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001012477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
BUSINESS PHONE: 636-449-1830
MAIL ADDRESS:
STREET 1: 16640 CHESTERFIELD GROVE ROAD
STREET 2: SUITE 200
CITY: CHESTERFIELD
STATE: MO
ZIP: 63005
FORMER COMPANY:
FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA
DATE OF NAME CHANGE: 19960422
4/A
1
doc1.xml
FORM 4/A
X0306
4/A
2017-12-15
2017-12-19
0
0001012477
AVADEL PHARMACEUTICALS PLC
AVDL
0001207106
STAPLETON CRAIG R
BLOCK 10-1, BLANCHARDSTOWN
CORPORATE PARK, BALLYCOOLIN
DUBLIN
L2
15
IRELAND
1
0
0
0
ADSs
2017-12-15
4
P
0
70000
8.671
A
323413
D
ADSs
2017-12-15
4
P
0
70000
8.671
A
180000
I
By Spouse
Warrants (right to buy)
14.54
2015-06-24
2018-06-24
ADSs
100000
100000
D
Warrants (right to buy)
21.67
2016-06-26
2019-06-26
ADSs
117449
117449
D
Warrants (right to buy)
13.59
2017-08-10
2020-08-10
ADSs
117449
117449
D
Stock Option (right to buy)
10.51
2018-06-28
2022-06-28
ADSs
30000
30000
D
The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3).
The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities.
Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS.
Warrants were granted 08/10/2016 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vested on 08/10/2017.
Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date.
This amendment to the Form 4 filed by the reporting person on December 19, 2017 (the "Previous Form 4") is being filed solely to correct the Transaction Code as reported in Column 3 of Table I of the Previous Form 4. Due to an administrative oversight, the Transaction Code in the Previous Form 4 was incorrectly listed as "A" for each transaction and has been corrected to "P" to reflect a purchase by the reporting person and the reporting person's spouse.
/s/ Phillandas T. Thompson, as attorney-in-fact for Craig R. Stapleton
2017-12-19